FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386046961> ?p ?o ?g. }

• W4386046961 endingPage "715" @default.
• W4386046961 startingPage "715" @default.
• W4386046961 abstract "Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD.To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries.Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years.Countries' per capita income levels and world region; individuals' socioeconomic demographics.Self-reported use of aspirin for secondary prevention of CVD.The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries.Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy." @default.
• W4386046961 created "2023-08-23" @default.
• W4386046961 creator A5003138186 @default.
• W4386046961 creator A5005935781 @default.
• W4386046961 creator A5008889924 @default.
• W4386046961 creator A5011942396 @default.
• W4386046961 creator A5022638664 @default.
• W4386046961 creator A5025277130 @default.
• W4386046961 creator A5028036780 @default.
• W4386046961 creator A5029635780 @default.
• W4386046961 creator A5031583448 @default.
• W4386046961 creator A5031793758 @default.
• W4386046961 creator A5032257928 @default.
• W4386046961 creator A5035870050 @default.
• W4386046961 creator A5035945329 @default.
• W4386046961 creator A5037811532 @default.
• W4386046961 creator A5039065157 @default.
• W4386046961 creator A5040203369 @default.
• W4386046961 creator A5040941938 @default.
• W4386046961 creator A5041478034 @default.
• W4386046961 creator A5045397336 @default.
• W4386046961 creator A5046704884 @default.
• W4386046961 creator A5048211551 @default.
• W4386046961 creator A5049061957 @default.
• W4386046961 creator A5050649371 @default.
• W4386046961 creator A5051724322 @default.
• W4386046961 creator A5054352048 @default.
• W4386046961 creator A5057245327 @default.
• W4386046961 creator A5062764105 @default.
• W4386046961 creator A5066629818 @default.
• W4386046961 creator A5068924308 @default.
• W4386046961 creator A5080371610 @default.
• W4386046961 creator A5082997556 @default.
• W4386046961 creator A5087123868 @default.
• W4386046961 creator A5090105475 @default.
• W4386046961 creator A5091066335 @default.
• W4386046961 date "2023-08-22" @default.
• W4386046961 modified "2023-09-23" @default.
• W4386046961 title "Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries" @default.
• W4386046961 cites W1480729244 @default.
• W4386046961 cites W2024352468 @default.
• W4386046961 cites W2043666180 @default.
• W4386046961 cites W2098194481 @default.
• W4386046961 cites W2100089051 @default.
• W4386046961 cites W2144663588 @default.
• W4386046961 cites W2147965610 @default.
• W4386046961 cites W2238687420 @default.
• W4386046961 cites W2594329719 @default.
• W4386046961 cites W2766581696 @default.
• W4386046961 cites W2811462708 @default.
• W4386046961 cites W2889654052 @default.
• W4386046961 cites W2945570808 @default.
• W4386046961 cites W3003055998 @default.
• W4386046961 cites W3021659692 @default.
• W4386046961 cites W3021842026 @default.
• W4386046961 cites W3023665549 @default.
• W4386046961 cites W3081758105 @default.
• W4386046961 cites W3092849554 @default.
• W4386046961 cites W3126697239 @default.
• W4386046961 cites W3197233987 @default.
• W4386046961 cites W3204300050 @default.
• W4386046961 cites W3212962851 @default.
• W4386046961 cites W4211207317 @default.
• W4386046961 cites W4223531324 @default.
• W4386046961 cites W4226093181 @default.
• W4386046961 cites W4226463531 @default.
• W4386046961 cites W4283692727 @default.
• W4386046961 cites W4283730346 @default.
• W4386046961 cites W4287575667 @default.
• W4386046961 cites W4293176633 @default.
• W4386046961 cites W4319303114 @default.
• W4386046961 doi "https://doi.org/10.1001/jama.2023.12905" @default.
• W4386046961 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37606674" @default.
• W4386046961 hasPublicationYear "2023" @default.
• W4386046961 type Work @default.
• W4386046961 citedByCount "0" @default.
• W4386046961 crossrefType "journal-article" @default.
• W4386046961 hasAuthorship W4386046961A5003138186 @default.
• W4386046961 hasAuthorship W4386046961A5005935781 @default.
• W4386046961 hasAuthorship W4386046961A5008889924 @default.
• W4386046961 hasAuthorship W4386046961A5011942396 @default.
• W4386046961 hasAuthorship W4386046961A5022638664 @default.
• W4386046961 hasAuthorship W4386046961A5025277130 @default.
• W4386046961 hasAuthorship W4386046961A5028036780 @default.
• W4386046961 hasAuthorship W4386046961A5029635780 @default.
• W4386046961 hasAuthorship W4386046961A5031583448 @default.
• W4386046961 hasAuthorship W4386046961A5031793758 @default.
• W4386046961 hasAuthorship W4386046961A5032257928 @default.
• W4386046961 hasAuthorship W4386046961A5035870050 @default.
• W4386046961 hasAuthorship W4386046961A5035945329 @default.
• W4386046961 hasAuthorship W4386046961A5037811532 @default.
• W4386046961 hasAuthorship W4386046961A5039065157 @default.
• W4386046961 hasAuthorship W4386046961A5040203369 @default.
• W4386046961 hasAuthorship W4386046961A5040941938 @default.
• W4386046961 hasAuthorship W4386046961A5041478034 @default.
• W4386046961 hasAuthorship W4386046961A5045397336 @default.
• W4386046961 hasAuthorship W4386046961A5046704884 @default.
• W4386046961 hasAuthorship W4386046961A5048211551 @default.

• next